Anti‐laminin γ1 (p200) pemphigoid successfully treated with tofacitinib combined with prednisone

The Journal of DermatologyEarly View LETTER TO THE EDITOR Anti-laminin γ1 (p200) pemphigoid successfully treated with tofacitinib combined with prednisone Xingli Zhou, Xingli Zhou orcid.org/0000-0001-7060-254X Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorYuxi Zhou, Yuxi Zhou orcid.org/0000-0002-9231-2794 Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorHua Qian, Hua Qian Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, ChinaSearch for more papers by this authorFanglong Wu, Fanglong Wu State Key Laboratory of Oral Diseases, National Center of Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Center for Dental Medicine Plus, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, ChinaSearch for more papers by this authorHongjie Liu, Hongjie Liu Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorXiaoguang Li, Corresponding Author Xiaoguang Li [email protected] orcid.org/0000-0001-6419-5693 Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China Correspondence Wei Li, Department of Dermatology and Rare Diseases Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu, China. Email: [email protected] Xiaoguang Li, Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China. Email: [email protected]Search for more papers by this authorWei Li, Corresponding Author Wei Li [email protected] orcid.org/0000-0002-9585-2884 Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China Correspondence Wei Li, Department of Dermatology and Rare Diseases Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu, China. Email: [email protected] Xiaoguang Li, Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China. Email: [email protected]Search for more papers by this author Xingli Zhou, Xingli Zhou orcid.org/0000-0001-7060-254X Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorYuxi Zhou, Yuxi Zhou orcid.org/0000-0002-9231-2794 Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorHua Qian, Hua Qian Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, ChinaSearch for more papers by this authorFanglong Wu, Fanglong Wu State Key Laboratory of Oral Diseases, National Center of Stomatology, National Clinical Research Center for Oral Diseases, Frontier Innovation Center for Dental Medicine Plus, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, ChinaSearch for more papers by this authorHongjie Liu, Hongjie Liu Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaSearch for more papers by this authorXiaoguang Li, Corresponding Author Xiaoguang Li [email protected] orcid.org/0000-0001-6419-5693 Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China Correspondence Wei Li, Department of Dermatology and Rare Diseases Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu, China. Email: [email protected] Xiaoguang Li, Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China. Email: [email protected]Search for more papers by this authorWei Li, Corresponding Author Wei Li [email protected] orcid.org/0000-0002-9585-2884 Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China Correspondence Wei Li, Department of Dermatology and Rare Diseases Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Wuhou District, Chengdu, China. Email: [email protected] Xiaoguang Li, Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University, Dalian, China. Email: [email protected]Search for more papers by this author First published: 21 June 2023 https://doi.org/10.1111/1346-8138.16864 Xingli Zhou and Yuxi Zhou contributed equally to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Kalantari Y, Sadeghi S, Asadi D, Goodarzi A. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders. Int Immunopharmacol. 2022; 110:108923. 2Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatol Ther. 2022; 35:e15754. 3Laufer Britva R, Amber KT, Cohen AD, Kridin K. Treatment and clinical outcomes in anti-p200 pemphigoid: a systematic review. J Eur Acad Dermatol Venereol. 2020; 34: 465–72. 4Meijer JM, Diercks GF, Schmidt E, Pas HH, Jonkman MF. Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. JAMA Dermatol. 2016; 152: 897–904. 5Tian SS, Tapley P, Sincich C, Stein RB, Rosen J, Lamb P. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood. 1996; 88: 4435–44. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation